Cypher Genomics

Cypher Genomics is a biotech startup that focuses on genome informatics, providing automated software solutions for the interpretation of human genomes. Their platform is designed to cater to clinical labs, pharmaceutical companies, and population genomics initiatives, unlocking the potential of human genome data for various applications. Founded in 2011 by Ashley Van Zeeland and based in La Jolla, California, Cypher Genomics has carved out a niche in the industry. Their innovative approach allows clinical laboratories to customize the sensitivity and specificity of Cypher Genomics' profiles, facilitating the development of molecular tests for diagnosis and prognosis. Moreover, pharmaceutical companies can leverage the platform to identify biomarkers using whole genome sequence data in early-stage drug development studies. This versatility makes Cypher Genomics a valuable asset in both clinical and research settings. The recent non-equity assistance investment at 01 November 2016 by EvoNexus signifies continued interest and support in Cypher Genomics' endeavors. Furthermore, the acquisition of Cypher Genomics by Human Longevity underscores the company's potential and the attractiveness of its technology in the market. In summary, Cypher Genomics is at the forefront of genome informatics, offering automated interpretation solutions that have garnered attention from investors and industry players alike. With its focus on clinical applications and pharmaceutical research, the company is well-positioned to make significant contributions to the evolving landscape of genomics and biotechnology.